摘要
目的探讨卵巢癌血清人附睾分泌蛋白4(HE4)、CA72-4、CA125水平及临床意义。方法入组我院收治的卵巢癌患者45例、卵巢良性病变30例,并纳入同期女性健康体检者30例作为对照,采用电化学发光法分别检测各组血清中HE4、CA72-4、CA125水平。结果卵巢癌组血清HE4、CA72-4、CA125水平均高于卵巢良性病变组和健康对照组(P<0.05)。HE4以>150 pmol·L-1,CA72-4以5.3 u·mL-1,CA125以35 u·mL-1为阳性参考值,三者联合检测的敏感性为93.3%,特异性为73.3%。结论卵巢癌患者血清中HE4、CA72-4、CA125处于高水平,联合检测可提高卵巢癌的诊断率。
Objective To investigate the serum levels and significance of human epididymis secretory protein 4 （ HE4）, CA72-4 and CA125 in patients with ovarian cancer. Methods Electro-chemical luminescent technique was used to detect the serum levels of HE4, CA72-4 and CA125 in 45 patients with ovarian cancer, 30 patients with benign ovarian lesions and 30 cases of healthy females. Results The serum levels of HE4, CA72-4 and CA125 in the ovarian cancer group was higher than those of the benign ovarian lesion group and the healthy control group （ P 〈0.05）. The sensitivity of combined detection was 93.3%, the specificity was 73.3%. Conclusion The serum levels of HFA, CA72-4 and CA125 are high in patients with ovarian cancer, combined detection can improve the di- agnosis rate of ovarian cancer.
出处
《肿瘤基础与临床》
2013年第6期522-523,共2页
journal of basic and clinical oncology
